Results 181 to 190 of about 259,208 (317)

Materials‐Guided Gene‐Ionizable Lipid Nanoparticles to Reverse Iron‐Associated Immune Resistance in Renal Cancer

Advanced Science, EarlyView.
ABSTRACT Iron overload is a common metabolic disturbance in cancer and contributes to poor outcomes in renal cell carcinoma (RCC), yet its effects on the tumour immune microenvironment remain unclear. Here we identify a previously unrecognized immunosuppressive axis in which iron overload downregulates the palmitoyltransferase ZDHHC12 in CD8+ T cells ...
Xin Jin, Yulong Hong, Chengliang Yin, Wanyang Guo, Yaxuan Wang, Ruijiang Zeng, Ruilin Liu, Zexian Ding, Xinlin Liu, Shangqing Ren, Qiyang Liang, Yaohui Wang, Xu Zhang, João Conde, Yuan Li, Xin Ma, Liangyou Gu   +16 more
wiley   +1 more source

Uveal melanoma: A review of current treatment limitations and the emerging therapeutic potential of natural killer cells. [PDF]

J Invest Dermatol
Narayana RVL, Lanier AL, Wajapeyee N, Gupta R.   +3 more
europepmc   +1 more source

Dual‐Stage Microneedle Patch With Lipid Droplet‐Mediated ‘Capture‐Kill’ and Sustained Release for Enhanced Wound Healing

Advanced Science, EarlyView.
We report a lipid‐droplet‐engineered, gallium‐loaded sonodynamic therapeutic platform (LDTG) incorporated into a bilayer microneedle (MN) patch co‐delivering all‐trans retinoic acid (ATRA), termed LDTG A‐MNs, for synergistic antibacterial therapy and accelerated wound repair.
Peng Jiang, Meijun Jiang, Jiapeng Lei, Wen Zhang, Huiyuan Yang, Xueyang Wang, Siyu Zhang, Qiongfang Ruan, Shuhua Liu, Wei Li   +9 more
wiley   +1 more source

Fifty Years of Natural Killer Cells: Milestones and Future Horizons. [PDF]

Scand J Immunol
Lundqvist A, Wagner AK, Chambers BJ, Dahlberg CIM, Sundbäck J, Cuapio A, Alici E, Ljunggren HG.   +7 more
europepmc   +1 more source

Amplification of Endoplasmic Reticulum Stress via Inhibiting Lipid Droplet Formation to Enhance Chemodynamic Immunotherapy

Advanced Science, EarlyView.
An endoplasmic reticulum (ER)‐targeted chemodynamic nanoagent (TCBQ/iLD‐ER NPs) comprising •OH‐generating tetrachloro‐1,4‐benzoquinone (TCBQ) and lipid droplets (LDs) formation inhibitor (iLD) is developed for chemodynamic immunotherapy of tumors. After ingestion by cancer cells, TCBQ/iLD‐ER NPs preferentially accumulate in the ER and react with ER ...
Huilan Cai, Shaoru Zhuang, Yang Zhu, Rujiang Ao, Meili Yu, Tingting Cui, Jun Wang, Xuegang Niu, Hongwei Huang, Shanshan Peng, Yu He, Lisen Lin, Huanghao Yang   +12 more
wiley   +1 more source

Improved expansion of peripheral blood and iPSC-derived natural killer cells for clinical applications. [PDF]

Cell Rep Methods
Thangaraj JL, Lopez E, Kaufman DS.
europepmc   +1 more source

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

Advanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan, Hongmei Yang, Renfei Wu, Meng Hao, Xiangpeng Chu, Chuxia Deng, Kathy Qian Luo   +6 more
wiley   +1 more source

Multidimensional plasticity of natural killer cells in tumours. [PDF]

Cell Death Dis
Yang X, Song Z, Chen L, Jia Q, Li M.
europepmc   +1 more source

A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates

Advanced Science, EarlyView.
Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao, Yan Deng, Jianjian Han, Yong Xie, Kai Bao, Lixin Ma, Lilong Liu, Wuxiang Mao   +7 more
wiley   +1 more source

Harnessing the power of natural killer cells in Lymphoma immunotherapy: Overcoming challenges and enhancing treatment options. [PDF]

Hematol Transfus Cell Ther
Roshandel E, Lasemi MV, Mehravar M, Salimi M, Majidi M, Mohammadali F, Seraji HR, Hajifathali A.   +7 more
europepmc   +1 more source